MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis

Ranny Van Weissenbruch* (Corresponding Author), Ludger Klimek, Gabriella Galffy, Melanie Emmeluth, Arkady Koltun, Ferdinand Kopietz, Duc Tung Nguyen, Hans Christian Kuhl, Wolfgang Pohl, Glenis K Scadding, David Price, Joaquim Mullol

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
3 Downloads (Pure)


Purpose: Patients with poorly controlled allergic rhinitis (AR) experience nasal symptoms, sleep disturbances, activity impairment, and decreased quality-of-life (QoL). MP-AzeFlu is safe and effective for moderate-to-severe seasonal and perennial AR, but its impact on QoL requires investigation in the real-world, especially among phenotypes of immunoglobulin (Ig)E-mediated AR. This subanalysis of an observational study evaluated response to MPAzeFlu via assessment of sleep quality and trouble with daily activities.
Patients and Methods: This multicenter, prospective, non-interventional, real-life study included a convenience sample of patients with a history of moderate-to-severe AR presenting with acute AR symptoms (visual analog scale [VAS] ≥50 mm). Over approximately 14 days of treatment with MP-AzeFlu (137 µg azelastine HCL and 50 µg fluticasone propionate administered via single 0.137-mL spray in each nostril twice daily), changes in sleep quality and trouble with daily work, school, social, and outdoor activities were evaluated using a VAS for the entire study population and for four subgroups based on IgE response phenotype. VAS scores ranged from “not at all troubled” (0 mm) to “extremely troubled” (100 mm).
Results: Following MP-AzeFlu treatment, mean VAS scores for sleep quality impairment and work or school impairment decreased from 55.2 mm at baseline to 22.1 mm and 57.6 mm at baseline to 23.0 mm, respectively, after ~14 days. Similar results were observed for mean VAS scores for impairment of social activity (55.1 mm to 22.4 mm) and impairment of outdoor activity (64.4 mm to 25.0 mm). For all VAS scores, results were similar across populations, regardless of phenotype of IgE-mediated disease, comorbidity, age, and sex.
Conclusion: MP-AzeFlu relieves symptoms and improves patient-reported QoL, illustrated by better sleep quality and less impairment of work, school, social, and outdoor activities after 14 days. The QoL benefits of MP-AzeFlu were consistent regardless of the phenotype of IgE-mediated disease.
Original languageEnglish
Pages (from-to)633—645
Number of pages13
JournalJournal of Asthma and Allergy
Publication statusPublished - 2 Dec 2020

Bibliographical note

We would like to thank the subjects who participated in the trial. The abstract of this paper was presented at the EAACI Congress 2020 as an oral presentation. The presentation’s abstract was published in Allergy: Van Weissenbruch R, Klimek L, Galffy G, et al. MP-Azeflu improves quality of life of patients with allergic rhinitis: a real-world study
Technical, editorial, and medical writing assistance were provided under the direction of the authors by Erin Burns, PhD, and Strategix, an affiliate of The Lynx Group, LLC. Funding for this support was provided by Mylan Inc.


  • azelastine hydrochloride
  • daily activities
  • fluticasone propionate
  • sleep


Dive into the research topics of 'MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis'. Together they form a unique fingerprint.

Cite this